Raoul Herbrecht

Summary

Country: France

Publications

  1. ncbi request reprint Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients
    Raoul Herbrecht
    Département d Hématologie et d Oncologie, Hopitaux Universitaires de Strasbourg, France
    J Clin Oncol 20:1898-906. 2002
  2. ncbi request reprint Managing the challenges of invasive fungal infections
    Raoul Herbrecht
    Int J Antimicrob Agents 27:1-2. 2006
  3. doi request reprint [Clinical and radiological aspects of mucormycosis]
    Raoul Herbrecht
    Département d oncologie et d hématologie, Hopital de Hautepierre, Hopitaux Universitaires de Strasbourg, Strasbourg, France
    Med Sci (Paris) 29:19-24. 2013
  4. doi request reprint Risk stratification for invasive aspergillosis in immunocompromised patients
    Raoul Herbrecht
    Department of Oncology and Hematology, Hopital de Hautepierre, Strasbourg, France
    Ann N Y Acad Sci 1272:23-30. 2012
  5. doi request reprint Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation
    Raoul Herbrecht
    pôle d oncologie et d hématologie, Hopital de Hautepierre, Strasbourg, France
    J Antimicrob Chemother 67:2731-8. 2012
  6. ncbi request reprint Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B
    R Herbrecht
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Avenue Moliere, 67098 Strasbourg, France
    Eur J Clin Microbiol Infect Dis 21:814-7. 2002
  7. ncbi request reprint Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion
    R Herbrecht
    Département d Onco Hématologie, Hopital de Hautepierre, Strasbourg, France
    Eur J Clin Microbiol Infect Dis 20:460-6. 2001
  8. ncbi request reprint The lipid formulations of amphotericin B
    Raoul Herbrecht
    Départment d Hématologie et d Oncologie, Hopital de Hautepierre, 67098 Strasbourg, France
    Expert Opin Pharmacother 4:1277-87. 2003
  9. ncbi request reprint Management of systemic fungal infections: alternatives to itraconazole
    R Herbrecht
    Department of Haematology and Oncology, Hopital de Hautepierre, 67098 Strasbourg, France
    J Antimicrob Chemother 56:i39-i48. 2005
  10. ncbi request reprint Invasive aspergillosis in the hematologic and immunologic patient: new findings and key questions in leukemia
    R Herbrecht
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
    Med Mycol 43:S239-42. 2005

Detail Information

Publications83

  1. ncbi request reprint Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients
    Raoul Herbrecht
    Département d Hématologie et d Oncologie, Hopitaux Universitaires de Strasbourg, France
    J Clin Oncol 20:1898-906. 2002
    ..To assess the Aspergillus galactomannan enzyme-linked immunosorbent assay (ELISA) in the diagnosis of invasive aspergillosis (IA) in adult and pediatric oncohematologic patients...
  2. ncbi request reprint Managing the challenges of invasive fungal infections
    Raoul Herbrecht
    Int J Antimicrob Agents 27:1-2. 2006
  3. doi request reprint [Clinical and radiological aspects of mucormycosis]
    Raoul Herbrecht
    Département d oncologie et d hématologie, Hopital de Hautepierre, Hopitaux Universitaires de Strasbourg, Strasbourg, France
    Med Sci (Paris) 29:19-24. 2013
    ..CT-scan or MRI are mandatory to assess the extension of the lesions. The diagnosis remains difficult and is often delayed resulting in a poor outcome...
  4. doi request reprint Risk stratification for invasive aspergillosis in immunocompromised patients
    Raoul Herbrecht
    Department of Oncology and Hematology, Hopital de Hautepierre, Strasbourg, France
    Ann N Y Acad Sci 1272:23-30. 2012
    ..The multiplicity of risk factors as well as the obvious synergy between them renders risk stratification difficult. An international, large-scale, multicenter, epidemiological study is necessary to develop a risk score...
  5. doi request reprint Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation
    Raoul Herbrecht
    pôle d oncologie et d hématologie, Hopital de Hautepierre, Strasbourg, France
    J Antimicrob Chemother 67:2731-8. 2012
    ..We describe diagnoses, therapeutic management and outcomes in unselected consecutive patients from haematological facilities treated for suspected or documented IFD...
  6. ncbi request reprint Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B
    R Herbrecht
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Avenue Moliere, 67098 Strasbourg, France
    Eur J Clin Microbiol Infect Dis 21:814-7. 2002
    ..Change of treatment to posaconazole given orally at 200 mg four times/d resulted in progressive improvement leading finally to cure after 24 weeks of therapy. Treatment with posaconazole was clinically and biologically well tolerated...
  7. ncbi request reprint Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion
    R Herbrecht
    Département d Onco Hématologie, Hopital de Hautepierre, Strasbourg, France
    Eur J Clin Microbiol Infect Dis 20:460-6. 2001
    ..No renal or hepatic toxicity was observed. These results compare favourably with the results of standard treatment and suggest that ABCD combined with surgery may be a useful therapy in patients with mucormycosis...
  8. ncbi request reprint The lipid formulations of amphotericin B
    Raoul Herbrecht
    Départment d Hématologie et d Oncologie, Hopital de Hautepierre, 67098 Strasbourg, France
    Expert Opin Pharmacother 4:1277-87. 2003
    ..Lipid formulations of amphotericin B are extremely expensive. Whether the increase in cost translates into a long-term benefit for the patient is still unknown...
  9. ncbi request reprint Management of systemic fungal infections: alternatives to itraconazole
    R Herbrecht
    Department of Haematology and Oncology, Hopital de Hautepierre, 67098 Strasbourg, France
    J Antimicrob Chemother 56:i39-i48. 2005
    ..The characteristics of these new agents are reviewed to help clinicians in their decision to select an antifungal agent for their patients...
  10. ncbi request reprint Invasive aspergillosis in the hematologic and immunologic patient: new findings and key questions in leukemia
    R Herbrecht
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
    Med Mycol 43:S239-42. 2005
    ..As these patients account for a majority of the aspergillosis cases, clinical trials on prophylaxis should not only be focused on allogeneic stem transplant recipients but also be designed for the patient with leukemia...
  11. ncbi request reprint Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections
    R Herbrecht
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
    Int J Clin Pract 58:612-24. 2004
    ..Posaconazole appears to be well tolerated over long-term administration (>1 year) and may represent an important addition to the anti-fungal armamentarium...
  12. ncbi request reprint Voriconazole: therapeutic review of a new azole antifungal
    Raoul Herbrecht
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, 67098 Strasbourg, France
    Expert Rev Anti Infect Ther 2:485-97. 2004
    ..apiospermum, and fluconazole-resistant serious invasive candida infections (including C. krusei)...
  13. doi request reprint Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study
    R Herbrecht
    Department of Oncology and Hematology, Hopital de Hautepierre, Strasbourg, France
    Bone Marrow Transplant 45:1227-33. 2010
    ..No patient had a drug-related serious adverse event or discontinued because of toxicity. Caspofungin first-line therapy was effective and well tolerated in allogeneic hematopoietic SCT patients with mycologically documented IA...
  14. ncbi request reprint Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient
    Raoul Herbrecht
    Department of Hematology and Oncology, Hopital de Hautepierre, Hopitaux Universitaires de Strasbourg, 67098 Strasbourg, France
    J Heart Lung Transplant 23:1451-4. 2004
    ..Posaconazole may provide effective treatment for difficult-to-treat Fusarium infections...
  15. ncbi request reprint Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
    Raoul Herbrecht
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
    N Engl J Med 347:408-15. 2002
    ..Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis...
  16. ncbi request reprint Can combination salvage therapy for invasive aspergillosis improve patient outcome?
    Raoul Herbrecht
    Hematology and Oncology Department, University Hospital of Strasbourg, France
    Nat Clin Pract Oncol 2:186-7. 2005
  17. ncbi request reprint Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients
    R Herbrecht
    Département d Hématologie et d Oncologie, H pital de Hautepierre, Strasbourg, France
    Eur J Clin Microbiol Infect Dis 20:77-82. 2001
    ..2 micromol/l at the end of therapy. These results support the use of ABLC in the treatment of invasive fungal infections in children, including patients who have previously failed, or are intolerant of, traditional antifungal regimens...
  18. ncbi request reprint [Visceral candidiasis]
    R Herbrecht
    Département d hématologie et d oncologie Hôpital de Hautepierre 67098 Strasbourg
    Rev Prat 51:725-30. 2001
    ..Amphotericin B deoxycholate or in lipid formulation and fluconazole are the antifungal drugs of choice. Removal of a central venous catheter should always be discussed in candidemia...
  19. ncbi request reprint Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment
    R Herbrecht
    Département d Hématologie et d Oncologie, H pitaux Universitaires de Strasbourg, France
    Drugs Aging 17:339-51. 2000
    ..New antifungal agents, especially new azoles, are under development. Their broad in vitro spectrum and preliminary clinical results are promising...
  20. ncbi request reprint [Lipid formulations of amphotericin B in the management of invasive fungal infections]
    Cécile Fohrer
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
    Therapie 61:235-42. 2006
    ..Nephrotoxicity was substantially higher in the loading dose arm and this contraindicates its use in clinical practice...
  21. ncbi request reprint Antifungal combination treatment: a future perspective
    Cécile Fohrer
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
    Int J Antimicrob Agents 27:25-30. 2006
    ..g. stem-cell transplant recipients). This paper examines the evidence available from in vitro, experimental, and clinical studies, and seeks to discover viable clinical strategies for this promising new therapeutic approach...
  22. doi request reprint Factors associated with overall and attributable mortality in invasive aspergillosis
    Yasmine Nivoix
    Pharmacie, Hopitaux Universitaires de Strasbourg, Strasbourg, France
    Clin Infect Dis 47:1176-84. 2008
    ..Invasive aspergillosis is associated with high death rates. Factors associated with increased mortality have not yet been identified in a large population of patients with various underlying conditions...
  23. ncbi request reprint Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors
    Raoul Santucci
    Pharmacy, Hopital Hautepierre, Avenue Moliere, 67000 Strasbourg, France
    Anticancer Res 30:963-5. 2010
    ..Delayed elimination of methotrexate associated with serious side-effects has been attributed to the co-administration of benzimidazole proton pump inhibitors...
  24. doi request reprint Adherence to recommendations for the use of antifungal agents in a tertiary care hospital
    Yasmine Nivoix
    Pharmacy, Hopitaux Universitaires de Strasbourg, Strasbourg, France
    J Antimicrob Chemother 67:2506-13. 2012
    ..The aim of our study was to assess the adherence to labelling and international guidelines for antifungal prescribing...
  25. doi request reprint Ventricular bigeminy associated with voriconazole, methadone and esomeprazole
    Julie Scholler
    Pharmacy, Hopital Hautepierre, Hopitaux Universitaires de Strasbourg, Avenue Moliere, 67000, Strasbourg, France
    Int J Clin Pharm 33:905-8. 2011
    ..This led to the large increase of the plasma concentration of methadone and was potentially responsible for its cardiac toxicity...
  26. ncbi request reprint Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2
    Catherine Helias
    Laboratory of Hematology, Hautepierre Hospital, Avenue Moliere, Strasbourg 67098, France
    Cancer Genet Cytogenet 180:51-5. 2008
    ..Gains on 9p being among the most common anomalies in PV, amplification of a gene or genes on this region may play a crucial role in the pathogenesis or evolution of PV...
  27. doi request reprint [Potential clinical impact of therapeutic education in patients treated with anticancer drugs]
    Raoul Santucci
    Hopitaux Universitaires de Strasbourg, pôle d oncologie et d hématologie, France
    Bull Cancer 98:176-81. 2011
    ..These data enlighten the importance of therapeutic education of cancer patients treated by chemotherapy...
  28. ncbi request reprint 13q deletions in B-cell lymphoproliferative disorders: frequent association with translocation
    Stephanie Struski
    Laboratoire d Hematologie, Hopital de Hautepierre, Avenue Moliere, 67098 Strasbourg, France
    Cancer Genet Cytogenet 174:151-60. 2007
    ..The very high frequency of 13q14 loss suggests that these deletions are of pathogenetic importance, but, the importance of the translocations remains to be determined...
  29. doi request reprint Breakthrough invasive mould infections in patients treated with caspofungin
    Katy Anna Phai Pang
    pôle d oncologie et d hématologie, Hopital de Hautepierre, Hopitaux Universitaires de Strasbourg, 1 Avenue Moliere, Strasbourg, France
    J Infect 64:424-9. 2012
    ..To describe and estimate the rate of breakthrough invasive mould diseases (IMD) in patients receiving caspofungin...
  30. doi request reprint The enzymatic basis of drug-drug interactions with systemic triazole antifungals
    Yasmine Nivoix
    Pôle Pharmacie Pharmacologie, Hopitaux Universitaires de Strasbourg, Strasbourg, France
    Clin Pharmacokinet 47:779-92. 2008
    ..These features are the basis of most interactions that occur during triazole therapy...
  31. ncbi request reprint Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care
    Yasmine Nivoix
    Pôle Pharmacie Pharmacologie, Hopitaux Universitaires de Strasbourg, Strasbourg, France
    Curr Drug Metab 10:395-409. 2009
    ..Therapeutic drug monitoring can help optimize treatment and prevent underdosing or overdosing of drugs. Education of patients and their families about signs and symptoms of possible drug interactions is also beneficial...
  32. doi request reprint Pharmacokinetic drug-drug interactions with methotrexate in oncology
    Dominique Leveque
    Hopital de Hautepierre, Hopitaux Universitaires de Strasbourg, 67000 Strasbourg, France dominique leveque chru strasbourg fr
    Expert Rev Clin Pharmacol 4:743-50. 2011
    ..This article summarizes reported drug-drug interactions involving methotrexate in clinical oncology with reference to the role of drug transporters that control the disposition of the antifolate agent...
  33. ncbi request reprint [New lipid formulations of amphotericin B. Review of the literature]
    E Andres
    Service de Medecine interne et nutrition, Hopital de Hautepierre, Avenue Moliere, 67098 Strasbourg, France
    Rev Med Interne 22:141-50. 2001
    ..This review analyzes the data available in the literature...
  34. pmc Successful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-up
    Stefano C H Kim
    Department of Hematology and Oncology, Centre des Hôpitaux Universitaires de Strasbourg, BP 67000, Strasbourg, France
    J Oncol 2010:812424. 2010
    ..She remains in complete remission six years after diagnosis. Conclusion. Granulocytic sarcoma of the cervix is a rare entity for which early intensive AML type therapy is effective...
  35. ncbi request reprint Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen
    Cécile Fohrer
    Department of Haematology and Oncology, Hopitaux Universitaires de Strasbourg, Strasbourg, France
    Br J Haematol 134:602-12. 2006
    ..Forty-one (32%) infections were recorded in 26 (79%) patients. This study demonstrated that an individual dose-adjustment of ACVBP regimen was manageable in PTLD patients and favourably impacted on long-term survival...
  36. pmc Disseminated Trichosporon mycotoxinivorans, Aspergillus fumigatus, and Scedosporium apiospermum coinfection after lung and liver transplantation in a cystic fibrosis patient
    Sandrine Hirschi
    Service de Pneumologie, Hopitaux Universitaires de Strasbourg, Strasbourg, France
    J Clin Microbiol 50:4168-70. 2012
    ..We report the first case of a disseminated fatal infection with T. mycotoxinivorans associated with invasive Aspergillus fumigatus and Scedosporium apiospermum infection after lung and liver transplantation in a cystic fibrosis patient...
  37. doi request reprint Comparative survival and cost of antifungal therapy: posaconazole versus standard antifungals in the treatment of refractory invasive aspergillosis
    Raoul Herbrecht
    Hopital de Hautepierre, Strasbourg, France
    Curr Med Res Opin 26:2457-64. 2010
    ..Refractory invasive aspergillosis (IA) is a life-threatening condition. Cost of treatment, although secondary, is important if newer drugs are to be widely accepted. Posaconazole has been shown to have activity against aspergillosis...
  38. ncbi request reprint [18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography for early evaluation of treatment efficacy in advanced non-Hodgkin lymphoma of uterine corpus: a case report
    Alessio Imperiale
    Service de Biophysique et de Medecine Nucleaire, Hopital de Hautepierre, 1 Avenue Moliere, 67098 Strasbourg Cedex, France
    Clin Lymphoma Myeloma 7:421-4. 2007
    ..Despite a theoretic risk of severe infectious complications, chemotherapy was well tolerated and resulted in a sustained complete remission...
  39. ncbi request reprint Clinical pharmacokinetics of voriconazole
    Dominique Leveque
    Department of Pharmacy, Hopital Hautepierre, Avenue Moliere, 67000 Strasbourg, France
    Int J Antimicrob Agents 27:274-84. 2006
    ..This review presents the published clinical pharmacokinetic data for the antifungal agent voriconazole. Aspects regarding absorption, tissue distribution, elimination and kinetic interactions are also discussed...
  40. ncbi request reprint Isolated renal Aspergillus abscess in an AIDS patient with a normal CD4+ cell count on highly active antiretroviral therapy
    D Rey
    Centre d Informations et de Soins de l Immunodéficience Humaine, Clinique Medicale A, Hopitaux Universitaires, Strasbourg, France
    Eur J Clin Microbiol Infect Dis 18:137-41. 1999
    ..In cases of Aspergillus renal abscess in HIV-infected patients, surgery is the treatment of choice, especially in the current era of highly active antiretroviral therapy...
  41. ncbi request reprint Fatal Aspergillus fumigatus Myositis in an immunocompetent patient
    R M Javier
    Service de Rhumatologie, Hĵpital de Hautepierre, Strasbourg, France
    Eur J Clin Microbiol Infect Dis 20:810-3. 2001
    ..Only six cases of Aspergillus myositis have been reported previously. All of them occurred in severely immunosuppressed patients and the outcome was fatal in all cases...
  42. ncbi request reprint Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections
    Y Nivoix
    Pharmacy Department of the University Hospital of Strasbourg, Avenue Moliere, 67098 Strasbourg, France
    J Infect 52:67-74. 2006
    ..Combination of caspofungin and another anti-fungal agent raise expectation of improved efficacy in severe fungal infections including failures to first line therapy...
  43. doi request reprint Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine
    Dominique Leveque
    Department of Pharmacy Pharmacology, Hopital de Hautepierre, Strasbourg, France
    Pharm World Sci 31:619-21. 2009
    ..Paralytic ileus was diagnosed by study imaging. Ileus lasted 10 days necessitating parenteral feeding. Later on, a further cycle of chemotherapy with etoposide replacing vincristine was given and was well tolerated...
  44. ncbi request reprint Improving the outcome of invasive aspergillosis: new diagnostic tools and new therapeutic strategies
    R Herbrecht
    Department of Hematology and Oncology, Hopital de Hautepierre, 67098 Strasbourg, France
    Ann Hematol 81:S52-3. 2002
  45. ncbi request reprint Cytogenetic studies of a series of 43 consecutive secondary myelodysplastic syndromes/acute myeloid leukemias: conventional cytogenetics, FISH, and multiplex FISH
    Wei Shali
    Laboratoire d Hematologie, Hopitaux Universitaires de Strasbourg, Avenue Moliere, 67098 Strasbourg, France
    Cancer Genet Cytogenet 168:133-45. 2006
    ..Compared to other series, recurrent translocations appeared to be more numerous (25%), probably reflecting an evolution of therapeutic modalities...
  46. pmc Cola beverage and delayed elimination of methotrexate
    Raoul Santucci
    Pharmacy Oncology and Hematology Department, Hopital de Hautepierre, Hopitaux Universitaires de Strasbourg, 67098 Strasbourg, France
    Br J Clin Pharmacol 70:762-4. 2010
    ..To report a case of severe delayed methotrexate elimination attributable to consumption of a cola beverage...
  47. ncbi request reprint Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients
    R Herbrecht
    , , France
    J Chemother 7:103-10. 1995
    ..In conclusion, isepamicin given once daily when combined with ceftriaxone in the treatment of febrile episodes in neutropenic cancer patients was as effective and no more toxic than amikacin...
  48. ncbi request reprint Chronic disseminated Trichosporon asahii infection in a leukemic child
    M H Meyer
    Institut de Parasitologie et de Pathologie Tropicale, Faculte de Medecine, Hopital de Hautepierre, 67000 Strasbourg, France
    Clin Infect Dis 35:e22-5. 2002
    ..This case report demonstrates that Trichosporon species can cause chronic disseminated disease with a pattern similar to that of disease caused by Candida species...
  49. ncbi request reprint Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)
    Oliver A Cornely
    1st Dept of Internal Medicine, University of Cologne, Germany
    Clin Infect Dis 44:1289-97. 2007
    ..Liposomal amphotericin B achieves maximum plasma levels at a dosage of 10 mg/kg per day, but clinical efficacy data for higher doses are lacking...
  50. pmc Successful outcome of treatment of a disseminated infection due to Fusarium dimerum in a leukemia patient
    Valerie Letscher-Bru
    Institut de Parasitologie et de Pathologie Tropicale, Faculte de Medecine, 67000 Strasbourg, France
    J Clin Microbiol 40:1100-2. 2002
    ....
  51. ncbi request reprint Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial)
    Denis Caillot
    Hematology Department, Dijon University Hospital Center, Dijon, France
    Cancer 110:2740-6. 2007
    ..Invasive aspergillosis (IA) has a poor prognosis in immunocompromised patients. Combinations of drugs that act on different targets are expected to improve the clinical efficacy of separate compounds...
  52. ncbi request reprint Beta-D-glucan detection test: a step toward preemptive therapy for fungal infections in leukemic patients?
    Raoul Herbrecht
    Clin Infect Dis 46:886-9. 2008
  53. doi request reprint Changes in causes of death over time after treatment for invasive aspergillosis
    John R Wingard
    Department of Medicine, University of Florida College of Medicine, Gainesville, Florida 32610 3633, USA
    Cancer 112:2309-12. 2008
    ..Assessment of response to invasive aspergillosis (IA) therapy has been challenging in treatment trials...
  54. doi request reprint Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America
    Thomas J Walsh
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Clin Infect Dis 46:327-60. 2008
  55. ncbi request reprint Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts
    Brahm H Segal
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Infect Dis 44:402-9. 2007
    ..Finally, we discuss the implications of newer antifungal agents and diagnostic adjuncts in the design of future clinical trials to evaluate prophylaxis and early prevention strategies...
  56. ncbi request reprint Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign
    Reginald E Greene
    Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Infect Dis 44:373-9. 2007
    ....
  57. pmc Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B
    Fritz Offner
    UZ Gent, Ghent, Belgium
    Antimicrob Agents Chemother 48:4808-12. 2004
    ..3%) patients, and hypokalemia was seen for 13 (39.4%). We conclude that liposomal nystatin can be effective for salvage therapy of invasive aspergillosis. Infusion-related adverse events have been observed frequently...
  58. ncbi request reprint The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview
    John H Rex
    AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom
    Clin Infect Dis 39:S165-9. 2004
    ..This supplement presents 12 articles by leading clinicians who are currently active in trials in this area and presents a current view of the unmet needs and challenges...
  59. ncbi request reprint Diagnosis of IPA in HIV: the role of the chest X-ray and radiologist
    Uta Zaspel
    Institut fur Radiologie, Charite Universitatsmedizin Berlin, Campus Mitte, Schuhmannstr 20 21, 10117 Berlin, Germany
    Eur Radiol 14:2030-7. 2004
    ..For internists with regular exposure to HIV patients, chest films do not provide information essential for the verification or differentiation of potential IPA...
  60. ncbi request reprint A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999
    Olivier Lortholary
    Centre National de Référence Mycologie et Antifongiques, Institut Pasteur, Paris and Hôpital Necker, Paris, France
    J Antimicrob Chemother 54:456-64. 2004
    ..To study the pharmacoepidemiology of the prescription of systemic antifungal agents in 48 French haematology, intensive care and infectious diseases units...
  61. ncbi request reprint Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
    Herve Tilly
    Department of Hematology, Centre Henri Becquerel, 76038 Rouen, France
    Blood 102:4284-9. 2003
    ..004). Despite higher toxicity, the ACVBP regimen, used as first-line treatment for patients with poor-risk aggressive lymphoma, is superior to standard CHOP with regard to both event-free survival and overall survival...
  62. ncbi request reprint A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations
    Jane P Barrett
    Jane Barrett Teaching and Consultancy, Cambridge, UK
    Clin Ther 25:1295-320. 2003
    ..A systematic review was performed to compare the effectiveness and tolerability of lipid-based amphotericin B (AmB) formulations and conventional AmB in the treatment of systemic fungal infections...
  63. ncbi request reprint Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 36:S123-7. 2003
    ....
  64. ncbi request reprint Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 36:S117-22. 2003
    ....
  65. ncbi request reprint Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis
    John E Bennett
    Clinical Mycology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Clin Infect Dis 36:S113-6. 2003
    ..An understanding of these features of design of antifungal drug trials is important in applying the results to clinical practice...
  66. ncbi request reprint Caspofungin: the first representative of a new antifungal class
    Valerie Letscher-Bru
    Institut de Parasitologie et de Pathologie Tropicale, Faculte de Medecine, 3 Rue Koeberle, 67000 Strasbourg, France
    J Antimicrob Chemother 51:513-21. 2003
    ..Further studies are required to define the exact role of caspofungin in the antifungal armamentarium...
  67. ncbi request reprint Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
    David W Denning
    North Manchester General Hospital, University of Manchester, Manchester, United Kingdom
    Clin Infect Dis 34:563-71. 2002
    ..Voriconazole is efficacious in treating acute IA...
  68. ncbi request reprint Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases
    Houria Mouas
    Service des Maladies Infectieuses et Tropicales, Hopital Necker, Paris, France
    Clin Infect Dis 40:1141-7. 2005
    ..BACKGROUND; Bone aspergillosis remains a rare but potentially devastating fungal disease. Although voriconazole is effective for invasive pulmonary aspergillosis, evidence of its efficacy for aspergillosis located in bone is limited...
  69. ncbi request reprint Risk factors for Gram-negative bacterial infections in febrile neutropenia
    Catherine Cordonnier
    Hematology Department, Henri Mondor Hospital, 94000 Creteil, France
    Haematologica 90:1102-9. 2005
    ..The objective of this study was to evaluate the risk of Gram-negative bacterial infections in febrile neutropenic patients and to develop a specific risk score...
  70. ncbi request reprint Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial
    Thomas J Walsh
    Immunocompromised Host Section, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Infect Dis 44:2-12. 2007
    ..Current treatments provide limited benefit. Posaconazole is an extended-spectrum triazole with in vitro and in vivo activity against Aspergillus species...
  71. ncbi request reprint Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis
    Johan Maertens
    Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium
    Cancer 107:2888-97. 2006
    ..Interest remains as to whether caspofungin, in combination with other antifungal classes, can improve the efficacy against IA...
  72. ncbi request reprint Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions
    Issam I Raad
    The M D Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Clin Infect Dis 42:1398-403. 2006
    ..Posaconazole is a broad-spectrum antifungal agent with in vitro and in vivo activity against Fusarium species...
  73. ncbi request reprint Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers
    Catherine Cordonnier
    Hopital Henri Mondor, AP HP and Université Paris 12, France
    Clin Infect Dis 42:955-63. 2006
    ..The goal of this retrospective and consecutive survey was to assess prognostic factors of death due to IA after HSCT at the time of diagnosis of IA...
  74. ncbi request reprint CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon and the Université Claude Bernard, Lyons, France
    N Engl J Med 346:235-42. 2002
    ..We conducted a randomized trial to compare CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B-cell lymphoma...
  75. ncbi request reprint Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome
    Thomas F Patterson
    Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    Clin Infect Dis 41:1448-52. 2005
    ..In that trial, treatment with voriconazole or amphotericin B deoxycholate could be followed with other licensed antifungal therapies (OLAT). Here, we report the impact of OLAT on the outcome of patients with invasive aspergillosis...
  76. ncbi request reprint Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
    Sylvain Choquet
    Hematology Unit, CHU La Pitié Salpêtrière Hospital, 47 bd de l Hopital, 75651 Paris Cedex 14, France
    Blood 107:3053-7. 2006
    ..We conclude that rituximab is effective and safe in PTLD, with stable responses at 1 year. The response rate and overall survival might be improved by combining rituximab with other treatments...
  77. pmc Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C
    Ben de Pauw
    Department of Blood Transfusion Service and Transplant Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Infect Dis 46:1813-21. 2008
    ..Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies...
  78. ncbi request reprint Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt
    Elias J Anaissie
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    Clin Infect Dis 43:1031-9. 2006
  79. ncbi request reprint Mycograb for the treatment of invasive candidiasis
    Raoul Herbrecht
    Clin Infect Dis 43:1083; author reply 1083-4. 2006
  80. ncbi request reprint Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy
    Catherine Cordonnier
    Hematology Department, University Paris XII, Henri Mondor Hospital, 94000 Creteil, France
    Clin Infect Dis 36:149-58. 2003
    ..7 in the presence of 1, 2, and > or =3 parameters, respectively. Risk factors for staphylococcal and streptococcal infections differ among neutropenic patients. A simple scoring system for predicting streptococcal infection is proposed...
  81. ncbi request reprint [Post-therapy surveillance in non-Hodgkin's lymphomas]
    Cécile Fohrer
    Département d hématologie et d oncologie Hôpital de Hautepierre, 67098 Strasbourg
    Rev Prat 52:986-90. 2002
    ..Late chemotherapy-related complications include second cancer (solid tumor, myelodysplastic syndrome and acute leukemia), cardiac and endocrine toxicity. Detection of these events also requires close clinical and biological monitoring...
  82. doi request reprint Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia
    Olivier Lortholary
    Universite Paris Descartes, Department of Infectious and Tropical Diseases, Centre d Infectiologie Necker Pasteur, Hopital Necker Enfants Malades, Paris, France
    Lancet Infect Dis 8:612-20. 2008
    ....
  83. ncbi request reprint Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on R
    Bertrand Coiffier
    Hematologie, CH Lyon Sud, 69495 Pierre Benite, France
    J Clin Oncol 21:4402-6. 2003
    ..This study was designed to evaluate the efficacy and the safety of rasburicase (recombinant urate oxidase) in adult patients with aggressive NHL during their first cycle of chemotherapy...